Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: Importance of optimal scheduling to exploit the ‘normalization’ window of the tumor vasculature
- 19 January 2006
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 244 (1) , 129-135
- https://doi.org/10.1016/j.canlet.2005.12.017
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Clinical applications of EPR: overview and perspectivesNMR in Biomedicine, 2004
- Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applicationsNMR in Biomedicine, 2004
- Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in TumorsCancer Research, 2004
- MRI for assessing antivascular cancer treatmentsThe British Journal of Radiology, 2003
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- Significance of angiogenesis in tumour progression and metastasisEuropean Journal Of Cancer, 1995
- Influence of an anti‐angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapyInternational Journal of Cancer, 1995
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 1991